Endometriosis is an age-related disease of the reproductive system, and its prevalence is up to 10% in premenopausal women worldwide. Its diagnosis is difficult because experienced obstetricians and gynecologists are required to correctly assess the clinical symptoms of the disease and assess the existence of ectopic endometrium in the abdominal cavity and pelvis [14]. Known hypotheses for endometriosis include embryonic origin, retrograde menstruation, and supraventricular metaplasia. However, many factors contribute to this complex pathogenesis, such as abnormal angiogenesis, an abnormal inflammatory response, estrogen dependence, genetic changes, and epigenetic changes, studies have shown that endometriosis is mainly affected by estrogen and progesterone. Estrogen promotes endometrial tissue proliferation, survival, and inflammation. However, the development, progression, infertility, and chronic pelvic pain of endometriosis are associated with progesterone resistance [15]. In recent years, more studies have been published on how to treat endometriosis. However, a radical cure is elusive, causing increased burdens to women of childbearing age and challenges to clinical work. Moreover, endometriosis has the characteristics of invasion and metastasis, very similar to tumor behavior, making the treatment of endometriosis a challenge clinically.
HSF1 is an evolutionarily conserved transcription factor that can respond to endogenous and exogenous cellular stresses by inducing HSP expression and ultimately maintaining intracellular protein stability. HSF1 responds to stress by up-regulating HSP27 and HSP40, however, HSP70 and HSP90 facilitate the refolding of misfolded proteins [16]. HSF1 can change the survival microenvironment of tumors, promoting their survival under harsh microenvironments and being related to their prognosis [17]. HSF1 plays an indispensable role in tumor migration, invasion, metastasis, proliferation, and cell metabolism. Therefore, HSF1 can be used as a tumor marker and a new therapeutic target [18] Based on endometriosis showing invasion and metastasis characteristics similar to those of tumors, we suspect that HSF1 plays a similar role in the development of endometriosis. Our hypothesis was supported by the finding that HSF1 promoted endometriosis growth through a series of experiments, including cell counting, cloning, and cell scratching.
The catalytic conversion of F-6-P to F-1,6-BP by PFK-1 is the main rate-limiting step in glycolysis, and the homeostatic state of F-1,6-BP is regulated by the bifunctional enzyme PFKFB. PFKFB has two regulatory domains: the 2-Kase domain, which has kinase activity and phosphorylates F-6-P to F-2,6-BP, and the 2-Pase domain, which has phosphatase activity and dephosphorylates F-2,6-BP back to F-6-P (Fig. 5E). There are four members of the PFKFB family, among which PFKFB3 has the highest kinase/phosphatase ratio and is a key enzyme in glycolysis. Therefore, many studies on glucose metabolism in cancer are based on PFKFB3, which has become a potential target for much drug development [19]. Because endometriosis cells must consume high amounts of energy in the process of migration and metastasis, glucose must be consumed. Additionally, when the effects of other key enzymes such as HK2 and PKM2 were excluded by real-time quantitative PCR, we found that HSF1 upregulated PFKFB3 expression to improve the glycolysis process, thus accelerating the development of endometriosis. Interestingly, these effects were reversed using the HSF1-specific inhibitor KRIBB11. KRIBB11 binds to HSF1 to prevent HSF1-dependent recruitment of p-TEFb to HSP70 promoters [20]. The effect of KRIBB11 was demonstrated both at the cellular level and in animal experiments.
Therefore, HSF1 is potential target for the treatment of endometriosis. By increasing the expression of PFKFB3, the efficiency of glycolysis can be rapidly improved. Importantly, HSF1 regulates glucose metabolism through PFKFB3, ultimately influencing the development of endometriosis. However, the regulatory role of HSF1 in endometriosis is complex, other compensatory mechanisms may be present. Many factors must be considered in future drug development and clinical applications, and we have provided some insight into the role of HSF1 in endometriosis. Further studies are warranted, but we believe our study has uncovered a new pathway to treat endometriosis.